Amgen vet Patrick Baeuerle inspires a $45M round from A-list VCs for a next-gen I/O drug platform
MPM founded Harpoon Therapeutics and seeded its early work looking to make the leap into next-gen immuno-oncology drugs with some insights from one of the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.